Both in Biotechnology
Moderna vs Exelixis
Over the past year MRNA returned +817.1% and EXEL returned +90.0%; their daily moves had a correlation of 0.26.
MRNA +817.1% EXEL +90.0%Growth of $1, one year, split-adjusted
| Metric | MRNA | EXEL |
|---|---|---|
| Price | $228.44 | $72.31 |
| Market cap | $91.20B | $17.64B |
| Today | +3.45% | +3.11% |
| 1 month | +12.4% | +22.9% |
| 6 months | +389.1% | +62.8% |
| Year to date | +674.6% | +65.0% |
| 1 year | +741.1% | +87.0% |
| Revenue growth (YoY) | +2.1% | +10.2% |
| Gross margin | 35.9% | 96.0% |
| Net margin | −539.3% | 33.1% |
| P/E (TTM) | — | 19.9× |
| Price / sales | 40.9× | 7.1× |
| Net cash | $4.54B | $892.0M |
| Dividend yield | — | — |
| Volatility (60d) | 230.1% | 26.8% |
| Short % of float | 9.0% | 11.4% |
| Next earnings | Nov 6, 2026 | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).